US 12,139,549 B2
Material and methods for treating or preventing HER-3 associated diseases
Thore Hettmann, Munich (DE); Daniel J. Freeman, Newbury Park, CA (US); and Robert Radinsky, Thousand Oaks, CA (US)
Assigned to DAIICHI SANKYO EUROPE GMBH, Munich (DE); and AMGEN INC., Thousand Oaks, CA (US)
Filed by DAIICHI SANKYO EUROPE GMBH, Munich (DE); and AMGEN INC., Thousand Oaks, CA (US)
Filed on Oct. 27, 2017, as Appl. No. 15/796,361.
Application 15/796,361 is a division of application No. 13/870,796, filed on Apr. 25, 2013, granted, now 9,803,025.
Application 13/870,796 is a division of application No. 12/944,764, filed on Nov. 12, 2010, granted, now 9,101,760, issued on Aug. 11, 2015.
Claims priority of provisional application 61/261,149, filed on Nov. 13, 2009.
Prior Publication US 2018/0134805 A1, May 17, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61N 5/10 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6851 (2017.08); A61K 47/6871 (2017.08); A61N 5/10 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. A method of treating a cancer expressing a HER-3 polypeptide comprising the sequence of SEQ ID NO: 389 in a human subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an isolated antibody or antigen-binding fragment thereof which binds to HER-3, comprising:
a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO: 256, a CDRH2 having the sequence of SEQ ID NO: 282, and a CDRH3 having the sequence of SEQ ID NO: 315; and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO: 340, a CDRL2 having the sequence of SEQ ID NO: 344, and a CDRL3 having the sequence of SEQ ID NO: 387;
and wherein said second agent is lapatinib.